53.7 F
San Diego
Thursday, Mar 28, 2024
-Advertisement-

Ionis Licenses Second Antisense Drug

Ionis Pharmaceuticals in Carlsbad has licensed another antisense drug to Janssen Biotech — this time receiving a $5 million fee — as part of a larger collaboration between the two companies.

Under the latest deal, Pennsylvania-based Janssen will take over all global development, regulatory and commercialization responsibilities for Ionis-JBI2-2.5, designed to treat a gastrointestinal autoimmune disease.

In July, Ionis partnered with Janssen on a different drug candidate for $10 million.

Through an agreement with Janssen, Ionis is eligible to receive nearly $800 million in development, regulatory and sales milestone payments and license fees. Ionis will also receive tiered royalties that (on average) are double-digits on sales from any product that is successfully commercialized, according to the company.

The agreement is in line with Ionis’ past strategy of focusing on drug discovery and partnering on commercialization.

-Advertisement-

Featured Articles

Oberon Eyes Europe for Renewable DME

Leaders of Influence in Law 2024

-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-
-Advertisement-